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High-dose
therapy with methotrexate has been used in the management of osteogenic sarcoma, acute lymphocytic leukemia, cancer of the head and neck, and other malignancies. Methotrexate acts as an antitumor agent by binding to the enzyme dihydrofolate reductase (EC 1.5.1.3) and preventing the formation of reduced folates that are necessary for many of the biochemical reactions involving the transfer of onecarbon units. As a result, synthesis of nucleic acids and DNA is inhibited. Several hours after methotrexate infusion, leucovorin (5-formyltetrahydrofolate) is given to "rescue" the normal cells from the toxic effects of methotrexate 
Materials and Methods

Specimens
All patients in this study were children who were receiving methotrexate in doses exceeding 50 mg/kg of body weight, followed by leucovorin "rescue." Blood was collected immediately and at 6 to 72 h after methotrexate infusion. The blood was centrifuged and the serum separated from the erythrocytes.
Apparatus
Two centrifugal analyzers, a "Multistat III" (Instrumentation Laboratories, Lexington, MA 02173) and a "CentrifiChem 400" (Union Carbide Corp Rye, NY 10580) were used in this study. With the diluter, pipet 3 iL of sample or standard and 48 iL of dihydrofolic acid solution together with 39 L of water into the sample compartment of the rotor. Pipet 225 1L of working reagent together with 10 ILL of water into the reagent compartment of the rotor. Pipet water into the reference position. Measure initial absorbance at 60s and the final absorbance at 120 s after the samples and reagents are mixed together. Measure the absorbances at a wavelength of 340 nm and at a temperature of 30 #{176}C. Use the change in absorbance between 60 and 120 s to calculate the concentration of methotrexate in the sample. Prepare a standard curve by plotting the changes in absorbances of the standards vs the concentrations on log-linear graph paper. Determine the methotrexate concentration in the samples from the standard curve. 
Reagents
Results and Discussion
Enzyme Inhibition Method As shown in Figure 1 , by increasing the antibody-substrate concentration, sensitivity is decreased because there is less free enzyme-drug (Figure 1 ). This may be the result of (a) a lack of available binding sites on the antibody, (b) decreased concentration of substrate, or (c) a combination of these two conditions.
5-Methyftetrahydrofolate
As shown in Figure 2 , by increasing the enzymedrug concentration, the sensitivity of the assay is increased. By decreasing the concentration of enzyme-drug, sensitivity is decreased because of the small amount of free enzyme-drug present in solution.
The proportions of antibody-substrate and enzyme-drug used in our procedure are those suggested by Syva.
Temperature.
To determine the effect of temperature on the assay we measured methotrexate standards at 30 and 37 #{176}C with use of the Multistat.
At 37 #{176}C, the #{163}4 values were significantly increased, resulting in a parallel shift of the standard curve when compared with that obtained at 30 #{176}C. At a methotrexate concentration of 0.2 ILmol/L the #{163}4 values are increased by 50%, at 2.0 ILmol/L by 30%.
Recovery.
We assessed the accuracy of the assay by adding methotrexate to seven serum samples and a cerebrospinal fluid specimen. The results are shown in Table 2 . For sera, analytical recoveries ranged between 88 and 100%, and averaged 96%. For the cerebrospinal fluid specimen, recoveries ranged between 100 and 106%, and averaged 102%.
Interferences.
All interference studies were determined with the Multistat centrifugal analyzer. Bilirubin in final concentrations ranging from 12.5 to 100 mgfL was added to a serum containing 1.3 ILmol of methotrexate per liter. No interference was observed.
The effect of lipemia was determined by serially diluting a lipemic sample with a serum containing a known quantity of methotrexate.
As shown in Table 3 , there was no interference from lipemia. Table 4 . There was However, the concentration of folic acid in serum is usually <100 Mmol/L, so it will not affect results of the methotrexate assay. Leucovorin, 5-methyltetrahydrofolate, 5-fluorouracil, and 6-mercaptopurine, each in concentrations up to 1.0 mmol/L, did not interfere with this assay.
Stability.
We determined the stability of methotrexate by storing three samples at 23,4, and -20 #{176}C. Methotrexate was stable in serum for at least five days at 23,4, or -20 #{176}C (Table  6) .
Precision.
The between-run precision of the method was determined during six days by use of the Multistat centrifugal analyzer.
The within-run precision of the assay was determined (Table 7) 
